GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » EBITDA Margin %

LENZ (LENZ Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LENZ Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-15.20 Mil. LENZ Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, LENZ Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


LENZ Therapeutics EBITDA Margin % Historical Data

The historical data trend for LENZ Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics EBITDA Margin % Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
- -69.83 - -

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LENZ Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, LENZ Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENZ Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's EBITDA Margin % falls into.


;
;

LENZ Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LENZ Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-58.552/0
= %

LENZ Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-15.2/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENZ Therapeutics  (NAS:LENZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


LENZ Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of LENZ Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


LENZ Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.